Dernières nouvelles pour Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Aptevo Therapeutics Inc

Green Brick Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRBK#NYSE">GRBK</a>) has outperformed the market over the past 10 years by 7.88% on an annualized basis producing an average annual return of 18.79%. Currently, Green Brick Partners has a market capitalization of $2.65 billion. 
Buying $1000 In GRBK: If an investor had bought $1000 of GRBK stock 10 years ago, it would be worth $6,130.66 today based on a price of $59.59 for GRBK at the time of writing.
<h3>Green Brick Partners's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750285813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

GRBK

Here's How Much You Would Have Made Owning Green Brick Partners Stock In The Last 10 Years

Apple is reportedly preparing to launch its first foldable iPhone, with a potential public release expected in 2026, according to analyst Ming-Chi Kuo of TF International Securities <a href="https://www.nbcnews.com/business/business-news/apple-looking-make-premium-priced-folding-iphones-starting-year-rcna213793">in </a>a NBC News report.
Kuo said in a post <a href="https://x.com/mingchikuo/status/1935381510296920525">on X:</a> &#8220;Assembly supplier Foxconn is expected to officially kick off the project in late 3Q25 or early 4Q25.&#8221; Kuo also said in March that the foldable device will target high-end consumers with <a href="https://www.benzinga.com/media/25/03/44165398/apples-foldable-ai-iphone-could-cost-over-2000-20-million-units-shipped-by-2027-analyst?utm_source=chatgpt.com">a premium price tag ranging from $2,000 to $2,500</a>.
Key hardware details — such as a stainless‑steel and titanium alloy hinge — are still under development, as Apple aims to minimize the screen crease and enhance durability, <a href="https://9to5mac.com/2025/06/18/kuo-apple-yet-to-finalize-many-foldable-iphone-specs/?utm_source=chatgpt.com">reported</a> 9to5Mac.com. Rumors suggest the device will feature a book‑style fold with a 7.8‑inch inner display and a 5.5‑inch external screen, measuring around 4.5 mm thin when open and 9–9.5 mm when closed
A Benzinga<a href="https://www.benzinga.com/media/25/03/44165398/apples-foldable-ai-iphone-could-cost-over-2000-20-million-units-shipped-by-2027-analyst?utm_source=chatgpt.com"> article</a> noted that Apple may ship 3–5 million units in 2026, ramping up to 20 million over the product cycle, signaling strong expectations despite the foldables market representing just 1%–3% of global smartphone sales today.
Analysts also suggest the device may include AI features tailored for multitasking and media, though Apple has not confirmed any specifications.
Huawei and Samsung, Apple rivals, have been releasing folding smartphones since 2019. 
While timelines remain fluid, Apple's entry could redefine foldable — if it solves key durability issues and delivers a polished user experience that goes beyond novelty.
Read Next: •&nbsp;<a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46006680/powell-holds-line-on-interest-rates-blames-tariff-uncertainty-for-delay-in-cuts">Why Powell Held Rates Steady, And What Trump&#8217;s Iran Comments Could Mean For Markets</a>
Photo: Wongsakorn 2468 on Shutterstock

Tech

Apple's Foldable iPhone May Arrive In 2026 With Premium Pricing, Sleek Design In Focus

General

FCPT

Four Corners Property Trust Acquires A Portfolio Of Automotive Service Properties For $4.7M From Vive Collision Via Sale Leaseback

In the current market session, Chord Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) share price is at $104.55, after a 2.16% decrease. Over the past month, the stock increased by 15.52%, but over the past year, it actually fell by 37.31%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1750284035_0.png" alt="Past Year Chart" />

<h3>Chord Energy P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 21.58 in the Oil, Gas &amp; Consumable Fuels industry, Chord Energy Inc. has a lower P/E ratio of 7.11. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750284035_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

CHRD

A Look Into Chord Energy Inc's Price Over Earnings

Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) has outperformed the market over the past 10 years by 3.26% on an annualized basis producing an average annual return of 14.18%. Currently, Fiserv has a market capitalization of $89.46 billion. 
Buying $1000 In FI: If an investor had bought $1000 of FI stock 10 years ago, it would be worth $3,750.81 today based on a price of $161.36 for FI at the time of writing.
<h3>Fiserv's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750284012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has outperformed the market over the past 5 years by 6.48% on an annualized basis producing an average annual return of 20.35%. Currently, Uber Technologies has a market capitalization of $174.57 billion. 
Buying $1000 In UBER: If an investor had bought $1000 of UBER stock 5 years ago, it would be worth $2,553.24 today based on a price of $83.48 for UBER at the time of writing.
<h3>Uber Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750283112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBER

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-06-18/amazon-orders-employees-to-relocate-to-seattle-and-other-hubs?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-18/amazon-orders-employees-to-relocate-to-seattle-and-other-hubs?embedded-checkout=true</a>

AMZN

'Amazon Orders Employees to Relocate to Seattle and Other Hubs'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-18/trump-tells-supreme-court-no-need-to-rush-to-consider-tariffs?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-18/trump-tells-supreme-court-no-need-to-rush-to-consider-tariffs?embedded-checkout=true</a>

'Trump Tells Supreme Court No Need to Rush to Consider Tariffs'- Bloomberg

Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) has outperformed the market over the past 10 years by 9.53% on an annualized basis producing an average annual return of 20.45%. Currently, Wix.com has a market capitalization of $8.82 billion. 
Buying $1000 In WIX: If an investor had bought $1000 of WIX stock 10 years ago, it would be worth $6,440.47 today based on a price of $158.50 for WIX at the time of writing.
<h3>Wix.com's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750282223_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250618-1478499/1478499_ussteel-x4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250618-1478499/1478499_ussteel-x4.pdf</a>

APi Group Set to Join S&P MidCap 400; Will Replace United States Steel Corp Effective Prior To The Opening Of Trading On Tuesday

<a href="https://www.nytimes.com/live/2025/06/18/world/israel-iran-trump">https://www.nytimes.com/live/2025/06/18/world/israel-iran-trump</a>

Politics

iShares MSCI Israel Capped Investable Market Index Fund

'Iran is open to talks with the U.S., a senior diplomat says, even as the supreme leader rejects the idea.'- New York Times

Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) has outperformed the market over the past 10 years by 36.54% on an annualized basis producing an average annual return of 47.45%. Currently, Advanced Micro Devices has a market capitalization of $205.74 billion. 
Buying $100 In AMD: If an investor had bought $100 of AMD stock 10 years ago, it would be worth $4,839.31 today based on a price of $126.89 for AMD at the time of writing.
<h3>Advanced Micro Devices's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750281345_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

<a href="https://www.wsj.com/livecoverage/iran-israel-conflict-news">https://www.wsj.com/livecoverage/iran-israel-conflict-news</a>

Macro Notification

'Trump Privately Approved Attack Plans For Iran But Has Withheld Final Order'- WSJ

<a href="https://www.reuters.com/business/media-telecom/putin-says-he-is-ready-talk-with-germanys-merz-2025-06-18/">https://www.reuters.com/business/media-telecom/putin-says-he-is-ready-talk-with-germanys-merz-2025-06-18/</a>

'Putin says he is ready to talk with Germany's Merz'- Reuters

In January 2025, following the unsolicited approach from Orbic to acquire Sonim, the Sonim Board formed a Special Committee to explore and evaluate a range of strategic alternatives to maximize stockholder value. Both strategically and tactically, the Special Committee has already found a potentially better alternative for Sonim stockholders to a transaction with Orbic. The Company provided further details in a letter to stockholders, highlights include:
<ul>
<li>Sale of Assets to Social Mobile: As announced on June 2, 2025, Sonim and Social Mobile have signed a Letter of Intent intended to lead to a definitive agreement under which Social Mobile will acquire substantially all of Sonim's operating assets for up to $20 million, including up to $5 million in earn-out consideration.</li>
<li>Reverse Takeover Transaction: Sonim intends to enter a definitive agreement with a prospective reverse takeover candidate in addition to the transaction with Social Mobile. The company is targeting a $15 million estimated value for Sonim. Together with the Social Mobile transaction, the aggregate potential value exceeds the value of Orbic's purported offer.</li>
<li>Orbic's Lack of Engagement: Despite the Special Committee's efforts to meaningfully engage, Orbic has demonstrated nothing but strategic inconsistency, abrupt tactical shifts, and adversarial behavior.</li>
<li>Orbic's Financial Distress: Orbic and its affiliates have more than $22.5 million in judgments against them, over ten lawsuits in the past decade, including disputes with customers, suppliers, employees, and business partners.</li>
<li>Orbic's Campaign and Illusory Proposal is an Attempt to Derail Strategic Alternatives Process: Sonim believes that Orbic's proxy contest is not about governance or performance—it is a continuation of Orbic's coercive strategy aimed at derailing Sonim's strategic alternatives process and an attempt to seize control of the Board and Company without paying a premium to all Sonim stockholders.</li>
</ul>

SONM

Sonim Technologies Announces Update on Strategic Alternatives Initiatives

<h3>Gainers</h3>
<ul>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares rose 6.2% to $2.74 during Wednesday's after-market session. The company's market cap stands at $9.3 million. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) stock increased by 5.16% to $1.63. The market value of their outstanding shares is at $91.6 million. </li>
<li>Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) stock moved upwards by 4.99% to $40.36. The company's market cap stands at $1.4 billion. </li>
<li>PubMatic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) stock rose 4.97% to $11.61. The market value of their outstanding shares is at $563.4 million. </li>
<li>PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) shares moved upwards by 4.43% to $2.12. The company's market cap stands at $96.5 million. </li>
<li>LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) stock rose 3.81% to $0.8. The market value of their outstanding shares is at $76.5 million. As per the news, the Q4 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PodcastOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODC#NASDAQ">PODC</a>) shares declined by 4.9% to $1.93 during Wednesday's after-market session. The company's market cap stands at $48.0 million. The company's, Q4 earnings came out today. </li>
<li>Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) shares fell 4.47% to $1.71. The company's market cap stands at $89.7 million. </li>
<li>Mega Matrix (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MPU#AMEX">MPU</a>) shares decreased by 4.45% to $0.85. The company's market cap stands at $34.6 million. </li>
<li>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) shares decreased by 3.6% to $5.36. The market value of their outstanding shares is at $1.0 billion. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) shares declined by 3.4% to $0.56. The market value of their outstanding shares is at $15.8 million. </li>
<li>Stran &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) shares declined by 3.38% to $1.43. The company's market cap stands at $26.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEHL

CDLX

LILA

NIPG

PODC

PSQH

PUBM

SPHR

SWAG

TNMG

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock moved upwards by 9.6% to $2.63 during Wednesday's after-market session. The market value of their outstanding shares is at $6.9 million. </li>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) shares increased by 8.93% to $3.17. The market value of their outstanding shares is at $137.0 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock rose 8.82% to $1.48. The market value of their outstanding shares is at $77.1 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 7.38% to $0.71. The company's market cap stands at $36.7 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock moved upwards by 7.37% to $0.74. The company's market cap stands at $96.5 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) stock increased by 6.96% to $4.76. The market value of their outstanding shares is at $20.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock declined by 15.3% to $6.79 during Wednesday's after-market session. The company's market cap stands at $40.4 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 10.59% to $0.76. The market value of their outstanding shares is at $2.0 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares decreased by 9.58% to $5.38. The market value of their outstanding shares is at $5.9 million. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) stock declined by 6.22% to $0.34. The market value of their outstanding shares is at $7.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock declined by 5.85% to $3.41. The market value of their outstanding shares is at $48.9 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock declined by 5.42% to $2.62. The market value of their outstanding shares is at $94.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

ATRA

CING

IMRX

KYTX

LIXT

MODV

PPBT

PROK

QNCX

TSBX

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock moved upwards by 6.7% to $1.59 during Wednesday's after-market session. The market value of their outstanding shares is at $17.4 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares rose 5.17% to $0.06. The market value of their outstanding shares is at $1.9 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares rose 4.8% to $2.39. The company's market cap stands at $74.9 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock rose 4.66% to $0.42. The company's market cap stands at $60.4 million. </li>
<li>United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) shares rose 4.5% to $1.62. The company's market cap stands at $14.9 million. </li>
<li>Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) shares moved upwards by 4.5% to $0.63. The market value of their outstanding shares is at $47.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) shares decreased by 9.6% to $1.5 during Wednesday's after-market session. The market value of their outstanding shares is at $63.1 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock fell 9.52% to $0.32. The company's market cap stands at $4.0 million. </li>
<li>CDT Envirn Tech Inv Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) shares fell 8.17% to $0.9. The market value of their outstanding shares is at $11.0 million. </li>
<li>C3is (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISS#NASDAQ">CISS</a>) stock fell 7.43% to $3.24. The company's market cap stands at $2.2 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock declined by 7.01% to $0.6. The market value of their outstanding shares is at $10.7 million. </li>
<li>T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) shares decreased by 6.02% to $1.38. The market value of their outstanding shares is at $215.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTOC

CDTG

CISS

HKPD

HOVR

ILAG

SCWO

UGRO

USEA

WLGS

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock rose 16.6% to $21.93 during Wednesday's after-market session. The market value of their outstanding shares is at $404.9 million. The company's, Q1 earnings came out today. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) stock rose 7.84% to $0.23. The company's market cap stands at $10.4 million. </li>
<li>Maris Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEK#NASDAQ">MTEK</a>) stock increased by 7.29% to $3.09. The market value of their outstanding shares is at $24.3 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) stock moved upwards by 6.34% to $0.44. The market value of their outstanding shares is at $8.7 million. </li>
<li>Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) shares increased by 6.27% to $2.54. The company's market cap stands at $152.3 million. </li>
<li>Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) stock moved upwards by 4.33% to $2.65. The market value of their outstanding shares is at $103.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock decreased by 15.2% to $0.13 during Wednesday's after-market session. The company's market cap stands at $4.8 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares declined by 14.73% to $0.35. The company's market cap stands at $9.8 million. </li>
<li>Verb Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) shares fell 10.61% to $5.9. The market value of their outstanding shares is at $8.3 million. </li>
<li>Zenvia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) shares decreased by 7.61% to $1.7. The company's market cap stands at $89.1 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) stock fell 6.67% to $2.8. The company's market cap stands at $20.5 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) stock decreased by 5.66% to $0.84. The company's market cap stands at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMBM

GRRR

LDTC

LTRX

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MINM

MTEK

SMSI

VERB

ZENV

ZEPP

12 Information Technology Stocks Moving In Wednesday's After-Market Session

<a href="https://www.theinformation.com/articles/meta-talks-hire-former-github-ceo-nat-friedman-daniel-gross-join-ai-efforts">https://www.theinformation.com/articles/meta-talks-hire-former-github-ceo-nat-friedman-daniel-gross-join-ai-efforts</a>

'Meta in Talks to Hire Former GitHub CEO Nat Friedman, Daniel Gross to Join AI Efforts'- The Information

Press Releases

$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Earnings

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

Events

Aptevo Participating in the BIO International Convention

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

APVO

OSRH

PNPNF

PRSO

TIVC

Aditxt

Alzamend Neuro

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

NuCana

Onconetix

Plus Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Roth MKM

WIIM

Aptevo Therapeutics shares are trading higher after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.

Comments

Aptevo Therapeutics

Actualités

Dernières nouvelles pour Aptevo Therapeutics (NASDAQ:APVO) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL